Alefacept

Summary

Alefacept (CHEMBL1201571) is an approved protein (ATC L04AA15) targeting CD2; indicated across 10 conditions including immune system disorder and psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L04AA15
• Targets: 1 (CD2)
• Indications: 10 conditions
• Clinical trials: 36

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201571
Name	Alefacept
Type	Protein
Max phase	4
ATC	L04AA15

Also known as: Alefacept, Amevive, BG-9273, BG-9712, BG9273, BG9712, Human lfa-3igg fusion protein, LFA-3CD2, LFA-3TIP, LFA3TIP, ALEFACEPT

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD2	CD2	Inhibition		0.2%	P06729

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	CD2
Cell surface interactions at the vascular wall	1	CD2

Dominant GO biological processes

GO term	Targets
membrane raft polarization	1
apoptotic process	1
immune response	1
cell surface receptor signaling pathway	1
natural killer cell activation	1
positive regulation of myeloid dendritic cell activation	1
positive regulation of type II interferon production	1
positive regulation of interleukin-8 production	1
positive regulation of tumor necrosis factor production	1
heterotypic cell-cell adhesion	1
T cell activation	1
natural killer cell mediated cytotoxicity	1
regulation of T cell differentiation	1
cell-cell adhesion	1
cell adhesion	1

Indications & clinical

Indications

10 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
immune system disorder	4	MONDO:0005046	EFO:0000540
psoriasis	3	MONDO:0005083	EFO:0000676
lichen planus	2	MONDO:0006572	EFO:1000726
psoriatic arthritis	2	MONDO:0011849	EFO:0003778
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
lymphoma	1	MONDO:0005062	EFO:0000574
aplastic anemia	1	MONDO:0015909	HP:0001915
kidney failure	1	MONDO:0001106	EFO:1002048

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 36.

Phase distribution

Phase	Trials
PHASE2	9
Not specified	9
PHASE4	8
PHASE3	5
PHASE1	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00168753	PHASE4	COMPLETED	Community Based Trial for AMEVIVE®
NCT00493324	PHASE4	COMPLETED	Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
NCT00655564	PHASE4	COMPLETED	Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
NCT00658606	PHASE4	COMPLETED	Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
NCT00794807	PHASE4	COMPLETED	Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00815633	PHASE4	TERMINATED	A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris
NCT00832585	PHASE4	COMPLETED	Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis
NCT00953329	PHASE4	TERMINATED	Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy
NCT00233662	PHASE3	COMPLETED	Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00361413	PHASE3	TERMINATED	Alefacept for Prevention of Graft Versus Host Disease (GVHD)
NCT00673556	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
NCT00674063	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
NCT00692172	PHASE3	COMPLETED	Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
NCT00135733	PHASE2	TERMINATED	A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
NCT00301002	PHASE2	COMPLETED	Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis
NCT00376129	PHASE2	COMPLETED	Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis
NCT00397332	PHASE1/PHASE2	COMPLETED	Alefacept for Chronic Graft Versus Host Disease
NCT00543569	PHASE2	COMPLETED	A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
NCT00617604	PHASE2	COMPLETED	A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
NCT00659412	PHASE2	COMPLETED	A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
NCT00808223	PHASE2	COMPLETED	Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
NCT00965458	PHASE2	TERMINATED	Inducing Remission in Type 1 Diabetes With Alefacept
NCT01226420	PHASE2	TERMINATED	Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
NCT00438802	PHASE1	COMPLETED	Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin’s Lymphoma
NCT00653822	PHASE1	COMPLETED	A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
NCT01163799	PHASE1	TERMINATED	A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
NCT01267643	PHASE1	TERMINATED	Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
NCT00167102	Not specified	COMPLETED	Alefacept in Patients With Severe Scalp Alopecia Areata
NCT00342862	Not specified	TERMINATED	AMEVIVE® Pregnancy Registry
NCT00407342	Not specified	COMPLETED	Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.
NCT00422617	Not specified	COMPLETED	Evaluate the Efficacy and Safety of One Course of Amevive in Taiwan Patients
NCT00454701	Not specified	TERMINATED	Assessment and Tracking of Long-term Alefacept Safety
NCT00678470	Not specified	COMPLETED	Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
NCT00795353	Not specified	TERMINATED	Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT01319851	Not specified	TERMINATED	Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
NCT01433770	Not specified	WITHDRAWN	Alefacept in Kidney Transplant Recipients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).